### Multiple pathways of type 1 interferon production in lupus: the case for amlexanox.

<table>
<thead>
<tr>
<th>Journal:</th>
<th>Rheumatology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID:</td>
<td>RHE-20-0856.R1</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Letter to the Editor (Other)</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>n/a</td>
</tr>
</tbody>
</table>
| Complete List of Authors: | Todd, Ian; University of Nottingham, School of Life Sciences  
Thomas, Rhema; University of Nottingham, School of Life Sciences  
Watt, Baltina; University of Nottingham, School of Life Sciences  
Sutherland, Lissa; University of Nottingham, School of Life Sciences  
Afriyie-Asante, Afrakoma; University of Nottingham, School of Life Sciences  
Deb, Bishnu; University of Nottingham, School of Life Sciences  
Joseph, Blessy; University of Nottingham, School of Life Sciences  
Tighe, Paddy; University of Nottingham, School of Life Sciences  
Lanyon, Peter; Nottingham University Hospitals NHS Trust, Queens Medical Centre  
Fairclough, Lucy; University of Nottingham, School of Life Sciences |
| Keywords: | Systematic lupus erythematosus and autoimmunity < RHEUMATIC DISEASES, Cytokines and inflammatory mediators < BASIC & CLINICAL SCIENCES, Inflammation < BASIC & CLINICAL SCIENCES, Immunosuppressants < THERAPIES, Immunotherapy < THERAPIES |
Letter to the Editor

Multiple pathways of type 1 interferon production in lupus: the case for amlexanox.

Ian Todd\textsuperscript{1,3}, Rhema E. Thomas\textsuperscript{1}, Baltina D. Watt\textsuperscript{1}, Lissa Sutherland\textsuperscript{1}, Afrakoma Afrivie-Asante\textsuperscript{1}, Bishnu Deb\textsuperscript{1}, Blessy Joseph\textsuperscript{1}, Patrick J. Tighe\textsuperscript{1,3}, Peter Lanyon\textsuperscript{2,3}, and Lucy C. Fairclough\textsuperscript{1,3}

\textsuperscript{1}School of Life Sciences, The University of Nottingham, UK; \textsuperscript{2}Department of Rheumatology, Nottingham University Hospitals NHS Trust, Nottingham, UK; \textsuperscript{3}Nottingham Biomedical Research Centre (Musculoskeletal), Nottingham University Hospitals NHS Trust, Nottingham, UK.

Correspondence to: Lucy C. Fairclough, School of Life Sciences, The University of Nottingham, Life Sciences Building, University Park, Nottingham, NG7 2RD, UK.

Key message: Amlexanox inhibits multiple pathways of type-1 interferon production and may be therapeutically useful in lupus.
Sir, Substantial evidence implicates type-1 interferons (IFN-1s) in the pathophysiology of systemic lupus erythematosus (SLE, lupus), and this has led to the development of several therapeutic strategies for lupus that target the IFN-1 pathways [1]. In particular, it has recently been reported that the therapeutic monoclonal antibody, anifrolumab, showed efficacy in meeting its primary endpoint in a phase III clinical trial in active lupus [2].

Anifrolumab targets the IFN-1 receptor and thereby inhibits the activity of all species of IFN-1 (α, β and ω). Overall, anifrolumab has shown greater promise in lupus than the therapeutic monoclonal antibodies that directly target IFN-α only (i.e. sifalimumab, rontalizumab) [1]. This is not surprising, as although many studies have concentrated on the role of IFN-α derived from plasmacytoid dendritic cells in lupus, it is now apparent that IFN-β and IFN-ω are also important in the pathophysiology [3]. With regard to the signalling pathways that are triggered in lupus to generate IFN-1 production, emphasis has been placed on the role of the DNA sensor TLR9 [4]. However, there is increasing evidence for the involvement of the RNA sensor TLR3, RNA sensors such as RIG-1/MDA-5 that stimulate MAVS, and the DNA sensors such as cGAS that stimulate STING [4-6]: all of these three pathways act via the signalling molecule TBK-1. Indeed, the type 1 IFN gene signature in peripheral blood mononuclear cells of childhood-onset lupus patients can be down-regulated by the TBK-1 inhibitor BX795 [5]. These and other findings have raised the potential of TBK-1 inhibitors as therapeutic agents for lupus [5].

Amlexanox is used for the topical treatment of aphthous ulcers and has been used to a limited degree in allergic asthma. We previously highlighted amlexanox from screening 1300 drugs for inhibitory effects on inflammatory signalling pathways [7] and it has been shown that amlexanox inhibits the IkB kinases TBK-1 and IKKε [8]. Based on its inhibition of TBK-1 and IKKε, amlexanox was recently used systemically in a randomized, double-blind, placebo-controlled clinical study in obese patients with type II diabetes and non-alcoholic fatty liver disease; it was shown to improve glucose control in a subset of patients with an inflammatory profile [9]. Only low-grade adverse side-effects were seen during the study. Importantly, therefore, this study demonstrated the clinical efficacy and safety of amlexanox when used systemically in patients [9].

Numerous subsequent studies in vitro and in animal models have demonstrated the effectiveness of amlexanox as a TBK-1 inhibitor (e.g. [10]) in a variety of pathological settings although, to our knowledge, no studies of amlexanox in relation to lupus have been reported to date. However, the potential of amlexanox in lupus is strongly supported by all of
these other studies. It is important, therefore, to be clear that amlexanox inhibits all three of
the pathways involving TBK-1 that may contribute to the production of IFN-1s in lupus.
(Most other studies have examined the inhibitory effects of amlexanox on just one or two of
these pathways; e.g. Raicevic et al. demonstrated that amlexanox inhibits IFN-β production
by mesenchymal stem cells stimulated via the RIG-1/MDA-5 pathway [10].)

In this regard, we now present evidence that amlexanox downregulates all three
pathways of TBK-1 activation involving TLR-3, RIG-1/MDA-5/MAVS or cGAS/STING in
the same cell type. For this we employed the lung epithelial carcinoma A549-Dual™
reporter cell line (Invivogen) that expresses Lucia luciferase under the control of IFN-
stimulated response elements. Thus, induction of luciferase expression acts as a surrogate for
IFN-1 production and is detected by the action of luciferase on the QUANTI-Luc™
detection reagent (Invivogen). The cells were cultured for 16h at 5x10^4/well in 96-well plates either
without ligands, or with one of the following: 50μg/mL Poly I:C (TLR-3 ligand), 0.1μg/mL
3p-hpRNA plus Lyovec (RIG-1/MDA-5 ligand), or 50μg/mL 2’3’cGAMP (STING ligand)
(all from Invivogen). The cells were cultured with or without 1μM amlexanox (Tocris
Bioscience). All the cultures contained dimethyl sulphoxide (1%) as a control as this was the
solvent for amlexanox. After 16h, 20μl aliquots of the culture supernatants were added to
50μl aliquots of QUANTI-Luc™ and the luminescence generated was immediately
measured.

The results shown in figure 1 for three to six independent experiments are expressed
as ratios of the luminescence values of supernatants from stimulated cells divided by the
luminescence values of supernatants from cells cultured without ligands or amlexanox.
These results show that amlexanox significantly inhibited the stimulation of the A549-Dual™
cells by all three ligands/pathways. Amlexanox did not induce death of the cells as
determined by trypan blue exclusion; cell death was only 2-3% on average following culture
without or with amlexanox (P=0.4).

Amlexanox did not affect the viability of the cells (data not shown).

These findings of the effects of amlexanox using the A549-Dual™ reporter cell line
should be confirmed in experiments with human peripheral blood mononuclear cells
(PBMCs), using synthetic ligands or sera from SLE patients to stimulate IFN-1 production.
Although these experiments are beyond the scope of this letter, we have preliminary data
showing that amlexanox inhibits IFN-β production by Poly I:C-stimulated PBMCs (data not
shown). However, our current data does show Our data therefore shows that amlexanox
inhibits all three pathways leading to TBK-1 activation and type 1 IFN production in response to particular forms of DNA or RNA ligands. We propose that this finding, together with the previous demonstration of the efficacy and safety of amlexanox administered systemically in a clinical trial in type II diabetes and non-alcoholic fatty liver disease [9], provides support for amlexanox to be considered for trials as a novel therapeutic agent in lupus.

Acknowledgements

The authors thank Colin Nicholson for technical assistance.

Funding: This work was supported by grants from LUPUS UK and The Nottingham Biomedical Research Centre (Musculoskeletal).

Disclosure statement: The authors have declared no conflicts of interest.

References


Figure legend

FIG 1. Amlexanox suppresses the activation of multiple signalling pathways involving TBK-1. A549-Dual™ cells were cultured for 16h with the indicated ligands (50µg/mL Poly I:C, 0.1µg/mL 3p-hpRNA plus Lyovec, or 50µg/mL 2’3’cGAMP), and with or without 1µM amlexanox. The culture supernatants were then tested for secreted luciferase by addition to QUANTI-Luc™ detection reagent. The results are presented as luminescence ratios of luciferase activity of ligand-stimulated cultures (without or with amlexanox) divided by the luciferase activity of non-stimulated cultures. Paired t-test was used to compare the readings in the absence or presence of amlexanox (p<0.05 considered significant).
FIG 1. A549-DualTM cells were cultured for 16h with the indicated ligands (50μg/mL Poly I:C, 0.1μg/mL 3p-hpRNA plus Lyovec, or 50μg/mL 2’3’cGAMP), and with or without 1μM amlexanox. The culture supernatants were then tested for secreted luciferase by addition to QUANTI-LucTM detection reagent. The results are presented as luminescence ratios of luciferase activity of ligand-stimulated cultures (without or with amlexanox) divided by the luciferase activity of non-stimulated cultures. Paired t-test was used to compare the readings in the absence or presence of amlexanox (p<0.05 considered significant).